D
Douglas S. Reintgen
Researcher at University of South Florida
Publications - 316
Citations - 26765
Douglas S. Reintgen is an academic researcher from University of South Florida. The author has contributed to research in topics: Sentinel lymph node & Melanoma. The author has an hindex of 84, co-authored 315 publications receiving 25912 citations. Previous affiliations of Douglas S. Reintgen include University of Texas Health Science Center at Houston & Duke University.
Papers
More filters
Journal ArticleDOI
Sentinel-node biopsy or nodal observation in melanoma
Donald L. Morton,John F. Thompson,Alistair J. Cochran,Nicola Mozzillo,Robert Elashoff,Richard Essner,Omgo E. Nieweg,Daniel F. Roses,Harald J Hoekstra,Constantine P. Karakousis,Douglas S. Reintgen,Brendon J. Coventry,Edwin C. Glass,He-Jing Wang +13 more
TL;DR: The staging of intermediate-thickness primary melanomas according to the results of sentinel-node biopsy provides important prognostic information and identifies patients with nodal metastases whose survival can be prolonged by immediate lymphadenectomy.
Journal ArticleDOI
Lymphatic mapping and sentinel node biopsy in the patient with breast cancer
J. Albertini,Gary H. Lyman,Charles E. Cox,Tim Yeatman,Ludovico Balducci,N. N. K. Ku,Steve Shivers,Claudia Berman,Wells Ke,Rapaport D,Alan R. Shons,John R. Horton,Harvey Greenberg,Santo V. Nicosia,Robert A. Clark,Alan B. Cantor,Douglas S. Reintgen +16 more
TL;DR: This study confirms that lymphatic mapping is technically possible in the patient with breast cancer and that the Histologic characteristics of the SLN probably reflect the histologic characteristicsof the rest of the axillary lymph nodes.
Journal ArticleDOI
Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.
Jeffrey E. Gershenwald,William A. Thompson,Paul F. Mansfield,Jeffrey E. Lee,Maria I. Colome,Chi-Hong Tseng,J. Jack Lee,Charles M. Balch,Douglas S. Reintgen,Merrick I. Ross +9 more
TL;DR: In this paper, the effect of pathologic sentinel lymph node (SLN) status with that of other known prognostic factors on recurrence and survival in patients with stage I or II cutaneous melanoma was compared.
Journal ArticleDOI
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
Douglas J. Schwartzentruber,David H. Lawson,Jon M. Richards,Robert M. Conry,Donald M. Miller,Jonathan S. Treisman,Fawaz Gailani,Lee B. Riley,Kevin C. Conlon,Barbara A. Pockaj,Kari Kendra,Richard L. White,Rene Gonzalez,Timothy M. Kuzel,Brendan D. Curti,Phillip D. Leming,Eric D. Whitman,Jai Balkissoon,Douglas S. Reintgen,Howard L. Kaufman,Francesco M. Marincola,Maria J. Merino,Steven A. Rosenberg,Peter L. Choyke,Don Vena,Patrick Hwu +25 more
TL;DR: In patients with advanced melanoma, the response rate was higher and progression-free survival longer with vaccine andInterleukin-2 than with interleuk in-2 alone.
Journal ArticleDOI
Validation of the Accuracy of Intraoperative Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma: A Multicenter Trial
Donald L. Morton,John F. Thompson,Richard Essner,Robert Elashoff,Stacey L. Stern,Omgo E. Nieweg,Daniel F. Roses,Constantine P. Karakousis,Nicola Mozzillo,Douglas S. Reintgen,He-Jing Wang,Edwin C. Glass,Alistair J. Cochran +12 more
TL;DR: The accuracy of LM/SL/SCLND was determined by comparing the rates of sentinel node (SN) identification and the incidence of SN metastases in the MSLT and JWCI groups.